Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160310 · ClinicalTrials.gov registry record
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
A clinical trial of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, sponsored by David M. Ritter.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06160310: Recruiting study of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, sponsored by David M. Ritter.
NCT06160310 is a study of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex that is actively recruiting participants, run by David M. Ritter. The registered enrollment target is 300 participants, below the 800-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06160310, a study of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex, is actively recruiting participants, sponsored by David M. Ritter.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
Primary Outcome
Assess number of days participant takes mTOR inhibitor in relation to number of days participant was supposed to take mTOR inhibitor.
Conditions Studied
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2029-07-01 |
What NCT06160310 shows while recruiting
NCT06160310 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 800-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 0 interventions.
NCT06160310 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06160310 about?
NCT06160310 is a clinical study titled "Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)". This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
What is the current status of trial NCT06160310?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-07-01. Estimated completion is 2029-07-01.
What conditions does trial NCT06160310 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis Complex.
Who is sponsoring clinical trial NCT06160310?
This trial is sponsored by David M. Ritter, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06160310 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06160310's enrollment target sits among peer trials
300 4th of 10 higher than 7 of 10 other Lymphangioleiomyomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphangioleiomyomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
Safety and Durability of Sirolimus for Treatment of LAM
RECRUITING
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Study of the Disease Process of Lymphangioleiomyomatosis
RECRUITING
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI